AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Talampicillin hydrochloride, through its active metabolite ampicillin, works by inhibiting bacterial cell wall synthesis. It interferes with the formation of peptidoglycan, a crucial component of the bacterial cell wall, leading to bacterial cell lysis and death. Ampicillin has activity against a wide range of gram-positive and gram-negative bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Escherichia coli, and some strains of Staphylococcus aureus.
Treatment of Bacterial Infections: Talampicillin hydrochloride is prescribed for the treatment of various bacterial infections, including respiratory tract infections (such as pneumonia, bronchitis, and sinusitis), urinary tract infections (UTIs), skin and soft tissue infections, otitis media, and bacterial gastroenteritis. It is often used for infections caused by susceptible organisms when oral therapy is appropriate.
Pharmacokinetics: Talampicillin hydrochloride is administered orally and is rapidly absorbed from the gastrointestinal tract. After absorption, it is converted to ampicillin, which achieves therapeutic concentrations in the bloodstream and tissues. Ampicillin is excreted primarily by the kidneys through urine, with a significant portion excreted unchanged.
Side Effects: Common side effects associated with talampicillin hydrochloride include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Allergic reactions, including skin rash, itching, and hives, may occur, particularly in individuals with a history of penicillin allergy. In rare cases, severe allergic reactions such as anaphylaxis may occur, requiring immediate medical attention. Ampicillin can also disrupt the normal balance of intestinal flora, leading to secondary infections such as candidiasis (yeast infection).
Drug Interactions: Talampicillin hydrochloride may interact with other medications, including oral contraceptives, leading to decreased contraceptive efficacy. It may also interact with certain drugs that affect renal function or undergo renal tubular secretion, potentially increasing the risk of toxicity.
Pregnancy and Lactation: The safety of talampicillin hydrochloride during pregnancy and lactation has not been well established. It should be used with caution in pregnant and breastfeeding women, and the potential risks and benefits should be carefully considered.
Medical Supervision: Talampicillin hydrochloride should be used under the guidance and supervision of a qualified healthcare professional. Patients should adhere to the prescribed dosage and duration of treatment to ensure optimal therapeutic outcomes and minimize the development of antibiotic resistance.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.5 | -0.5 | |
ADHD | 7.5 | 1 | 6.5 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 3 | 2.5 | 0.2 |
Allergies | 7.2 | 4.5 | 0.6 |
Allergy to milk products | 2.5 | 1.5 | 0.67 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 5.7 | 8.7 | -0.53 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 5.7 | 2.5 | 1.28 |
Ankylosing spondylitis | 6.5 | 3 | 1.17 |
Anorexia Nervosa | 0.5 | 3.5 | -6 |
Antiphospholipid syndrome (APS) | 2.5 | 2.5 | |
Asthma | 2 | 2.5 | -0.25 |
Atherosclerosis | 2 | 3.5 | -0.75 |
Atrial fibrillation | 5.5 | 3 | 0.83 |
Autism | 16.2 | 14.7 | 0.1 |
Barrett esophagus cancer | 1 | 0.5 | 1 |
benign prostatic hyperplasia | 0.5 | 0.5 | |
Bipolar Disorder | 2 | 2.5 | -0.25 |
Brain Trauma | 1 | 1 | 0 |
Carcinoma | 5.5 | 4 | 0.38 |
Celiac Disease | 4 | 6 | -0.5 |
Cerebral Palsy | 2.5 | 2 | 0.25 |
Chronic Fatigue Syndrome | 8.6 | 10 | -0.16 |
Chronic Kidney Disease | 4 | 3 | 0.33 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3.5 | 1.5 | 1.33 |
Chronic Urticaria (Hives) | 3 | 2.7 | 0.11 |
Coagulation / Micro clot triggering bacteria | 2.5 | 2 | 0.25 |
Colorectal Cancer | 7.7 | 1.5 | 4.13 |
Constipation | 2.5 | 1 | 1.5 |
Coronary artery disease | 2.5 | 1.5 | 0.67 |
COVID-19 | 18 | 22 | -0.22 |
Crohn's Disease | 12.7 | 9.2 | 0.38 |
cystic fibrosis | 1.5 | 1.5 | 0 |
deep vein thrombosis | 1.5 | 1.5 | 0 |
Depression | 15.9 | 14 | 0.14 |
Dermatomyositis | 0.5 | 0.5 | 0 |
Eczema | 2 | 3.2 | -0.6 |
Endometriosis | 5 | 2 | 1.5 |
Eosinophilic Esophagitis | 0.5 | 0.5 | 0 |
Epilepsy | 4.7 | 4.5 | 0.04 |
Fibromyalgia | 4.5 | 4.5 | 0 |
Functional constipation / chronic idiopathic constipation | 9.2 | 6.2 | 0.48 |
gallstone disease (gsd) | 3.5 | 1.5 | 1.33 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.7 | 1.5 | 0.8 |
Generalized anxiety disorder | 3.5 | 3 | 0.17 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 2 | 2 | 0 |
Halitosis | 1.5 | 0.5 | 2 |
Hashimoto's thyroiditis | 4 | 1 | 3 |
Hidradenitis Suppurativa | 1 | 0.5 | 1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 5.5 | 1.5 | 2.67 |
hypercholesterolemia (High Cholesterol) | 1 | 1 | 0 |
hyperglycemia | 0.5 | 3.5 | -6 |
Hyperlipidemia (High Blood Fats) | 1.5 | 0.5 | 2 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 4 | 7.2 | -0.8 |
Hypothyroidism | 2 | -2 | |
Hypoxia | 1.5 | 1.5 | |
IgA nephropathy (IgAN) | 6 | -6 | |
Inflammatory Bowel Disease | 7.7 | 13.7 | -0.78 |
Insomnia | 1.5 | 1.5 | 0 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 2 | 0.5 | 3 |
Irritable Bowel Syndrome | 6.5 | 7 | -0.08 |
Liver Cirrhosis | 7.5 | 5 | 0.5 |
Long COVID | 12.7 | 12.5 | 0.02 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 1.5 | 2.5 | -0.67 |
ME/CFS with IBS | 1.7 | 4 | -1.35 |
ME/CFS without IBS | 3.5 | 3.5 | 0 |
Menopause | 3 | 3 | |
Metabolic Syndrome | 12.7 | 13.5 | -0.06 |
Mood Disorders | 20.4 | 14.5 | 0.41 |
multiple chemical sensitivity [MCS] | 2.5 | 0.5 | 4 |
Multiple Sclerosis | 9.5 | 8.7 | 0.09 |
Multiple system atrophy (MSA) | 3.5 | 1.5 | 1.33 |
Neuropathy (all types) | 1.5 | 0.5 | 2 |
neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 8.5 | -1.13 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 13.5 | 8.5 | 0.59 |
obsessive-compulsive disorder | 10.7 | 7.5 | 0.43 |
Osteoarthritis | 4 | 0.5 | 7 |
Osteoporosis | 3 | 2 | 0.5 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 5.5 | 6.7 | -0.22 |
Polycystic ovary syndrome | 4 | 3.5 | 0.14 |
Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
Premenstrual dysphoric disorder | 1.5 | 0.5 | 2 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 7.2 | 5 | 0.44 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 11 | 5.7 | 0.93 |
Rosacea | 2 | 1 | 1 |
Schizophrenia | 11 | 3 | 2.67 |
scoliosis | 0.5 | 1.5 | -2 |
Sjögren syndrome | 5 | 5 | 0 |
Sleep Apnea | 2.5 | 2.5 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 1 | 1 |
Stress / posttraumatic stress disorder | 5 | 4.5 | 0.11 |
Systemic Lupus Erythematosus | 6.7 | 3 | 1.23 |
Tic Disorder | 2 | 2.5 | -0.25 |
Tourette syndrome | 0.5 | 0.5 | 0 |
Type 1 Diabetes | 5.7 | 4 | 0.43 |
Type 2 Diabetes | 13.2 | 11 | 0.2 |
Ulcerative colitis | 5 | 9 | -0.8 |
Unhealthy Ageing | 9.4 | 3.5 | 1.69 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.